CB-03-01 (cortexolone 17α-propionate, CB0301) 1% cream is a topical androgen receptor inhibitor which has mainly been developed for the treatment of acne vulgaris (1). It is also presently being investigated in a large phase II clinical trial for the topical treatment of male-pattern baldness. CB-03-01 has been found to inhibit the androgen receptor regulated pathway (1). Also known as clascoterone, CB-03-01 is being developed by Cassiopea (a spin-off company from Cosmo Pharmaceuticals) and was initially commercialised as Breezula. Data from 2020 reveal that clascoterone is also being marketed as Winlevi for the management of acne vulgaris. CB-03-01 is thought to compete with DHT for its binding to androgen receptors in both the sebaceous gland and dermal papilla cells within hair follicles. The difference between Winlevi and Breezula is that Breezula is a solution that contains a higher concentration of the drug for the treatment of male-pattern baldness(2). In 2019, Cassiopea announced positive phase II 12-month results for their flagship product Breezula in the management of androgenetic alopecia. The phase II clinical trial recruited in excess of 400 participants in Germany and sought to evaluate the efficacy and safety of 4 different dosing regimens of CB-03-01 compared to vehicle agents in male subjects between the ages of 18 and 55 with mild to moderate male-pattern baldness. All participants were randomised to either apply CB-03-01 or a vehicle agent to balding areas of the scalp daily for 12 months. 5 treatment groups were analysed – 2.5% solution twice-daily, 5.0% solution twice-daily, 7.5% solution twice-daily, 7.5% solution once-daily, and vehicle solution twice-daily.
Researchers used target area hair count (TAHC) and hair growth assessment (HGA) score as the primary end-points of interest. For TAHC, statistically significant changes versus the vehicle agent were observed in all of the active treatment groups, with the most significant improvements observed in the 7.5% twice-daily
cas: 35084-48-1 ACA Nootropic Powder pyrrolidine-2-carboxylic acid
ACA 1-(1 adamantyl carbonyl proline) strengthening the brain promotes intelligence, refreshes, and promotes the development of damaged brain neurons
ACA is smoother than modafinil and blessed with anxiolytic properties. Increased focus is comparable with the afinil family but doesn't seem to leave a crash.
Adamantyl effects are due to an increase in dopamine synthesis, release inhibition uptake and norepinephrine stimulation.
cas: 121062-08-6 MelanotanII acetate salt Melanotan II peptides
MELANOTAN II AND MELANIN PRODUCTION
Melanotan II (MT2) is a stimulating peptide which induces skin tanning. Melanocyte Stimulating Hormones (MSH) are a class of peptide hormones produced in the intermediate lobe of the pituitary gland that stimulate pigment cells (melanocytes) in the skin and hair to produce and release melanin which leads to darker skin and hair. Melanotan II increases melanin production via stimulation of skin pigment cells called melanocytes.
WHAT IS MELANIN?
Melanin is the skin pigment produced that protects our skin from sun’s UV radiation and damage. It could be considered our body’s own natural sunscreen. Low levels of melanin mean that the skin is highly susceptible to DNA damage with excess sun exposure. This lack of melanin and its protection against UV radiation means that those individuals with fair skin have a propensity to burn and risk more DNA damage. It also means that a lot of time is invested their ability to develop a tan safely without burning.
Receiving an adequate supply of vitamin D from the sun without being at risk of developing melanoma is somewhat of a balancing act. Studies have already discovered that staying out of the sun to prevent melanoma can cause vitamin D deficiency.
Stimulate Melanin Production with Tanning Peptides
To get a safe tan, we need to stimulate the melanocyte stimulating hormone responsible for increasing melanin production.
Scientists discovered the use of a “tanning peptide” when investigating possible ways to treat skin cancer. They hypothesized that by inducing the body’s natural pigmentary system through the process of melanogenesis, a protective tan could be produced before UV exposure, thereby reducing the potential for skin damage.
With just a little UV exposure, the release of a- Melanocyte Stimulating Hormone stimulates a natural increase in the production of melanin from the melanocytes in the skin. Use of the tanning peptide provides more a-MSH which results in more melanin being produced and greater tanning potential (skin pigmentation) regardless of your skin type.
Clinical trials have shown that use of Melanotan II may hold the potential to promote melanogenesis, with minimal side effects. The primary role of melanogenesis is to protect the hypodermis, which is the layer under the skin from the UV-B light that causes damage. It works by absorbing all of the UV-B light, which blocks its passage into the skin layer.
cas: 1093861-60-9 Anthelmintic Drug Afoxolaner
CBNumber: CB72717660
Chemical Name: afoxolaner
Molecular Formula: C26H17ClF9N3O3
Formula Weight: 625.87
CAS No.: 1093861-60-9
Afoxolaner is the active principle of the veterinary medicinal products (alone), Frontpro (alone) and Spectra (in combination with milbemycin oxime). They are indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations in dogs and puppies (8 weeks of age and older, weighing 4 pounds (~1.8 kilograms) of body weight or greater) for one month. These products are administered orally and poisons fleas once they start feeding.
How do I give my dog afoxolaner?
Afoxolaner is given by mouth in the form of a chewable tablet. The tablet should always be given as directed by your veterinarian. It can be given with or without food or water. Be sure the dog consumes the entire dose. If your dog vomits within 2 hours of dosing, give another full dose. Try giving the next dose with food.
afoxolaner contains afoxolaner which is absorbed into the bloodstream after ingestion. When fleas and ticks ingest blood containing afoxolaner, it causes hyperexcitation and death in these parasites.
cas: 17650-98-5 ceruletide
CBNumber: CB2384634
Chemical Name: CAERULEIN
Molecular Formula: C58H73N13O21S2
Formula Weight: 1352.4
CAS No.: 17650-98-5
Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.
Ceruletide (INN), also known as cerulein or caerulein, is a ten amino acid oligopeptide that stimulates smooth muscle and increases digestive secretions. Ceruletide is similar in action and composition to cholecystokinin. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction. It is used to induce pancreatitis in experimental animal models.
Ceruletide is a synthetic decapeptide that resembles cholecystokinin and causes contraction of the gallbladder. It has been used instead of the traditional “fatty meal” in cholecystography, as an aid in X-ray examination of the small bowel, and to evaluate exocrine pancreatic function ; it has also been used to treat postoperative ileus, intestinal atonia, and chronic fecal stasis , and to treat retained bile stones
cas: 187389-52-2 Z-VAD-FMK Caspase Inhibitor I
Chemical Name: Z-VAD-FMK
Molecular Formula: C22H30FN3O7
Formula Weight: 467.49
CAS No.: 187389-52-2
Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor, Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1
cas: 225779-44-2 PAR-4(1-6)(human)
Chemical Name: H-GLY-TYR-PRO-GLY-GLN-VAL-OH
Molecular Formula: C28H41N7O9
Formula Weight: 619.67
CAS No.: 225779-44-2
PAR-4 (1-6) (human) is an N-terminal fragment of protease-activated receptor 4 (PAR4) that acts as a PAR4 agonist. PAR-4 (1-6) (human) induces aggregation of human platelets